RU2004129752A - Гетероциклические амидные промзводные для лечения диабета и других заболеваний - Google Patents

Гетероциклические амидные промзводные для лечения диабета и других заболеваний Download PDF

Info

Publication number
RU2004129752A
RU2004129752A RU2004129752/04A RU2004129752A RU2004129752A RU 2004129752 A RU2004129752 A RU 2004129752A RU 2004129752/04 A RU2004129752/04 A RU 2004129752/04A RU 2004129752 A RU2004129752 A RU 2004129752A RU 2004129752 A RU2004129752 A RU 2004129752A
Authority
RU
Russia
Prior art keywords
compound according
carbon atoms
alkyl
oxo
substituted
Prior art date
Application number
RU2004129752/04A
Other languages
English (en)
Russian (ru)
Inventor
Магнус ПФАЛЬ (US)
Магнус ПФАЛЬ
Кэтрин ТАЧДЖИАН (US)
Кэтрин ТАЧДЖИАН
Хуссин А. АЛЬ-ШАММА (US)
Хуссин А. АЛЬ-ШАММА
Андреа Фаньюль ДЖАКИНО (US)
Андреа Фаньюль ДЖАКИНО
Карин ЯКУБОВИЧ-ЖАЙАРДОН (FR)
Карин ЯКУБОВИЧ-ЖАЙАРДОН
Цз ньхуа ГО (US)
Цзяньхуа ГО
Мохамед БУДЖЕЛАЛ (US)
Мохамед БУДЖЕЛАЛ
Джеймс В. ЦАПФ (US)
Джеймс В. ЦАПФ
Original Assignee
Инсайт Сан Диего Инкорпорейтед (Us)
Инсайт Сан Диего Инкорпорейтед
Орто-Макнейл Фармасьютикал Инк. (Us)
Орто-Макнейл Фармасьютикал Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инсайт Сан Диего Инкорпорейтед (Us), Инсайт Сан Диего Инкорпорейтед, Орто-Макнейл Фармасьютикал Инк. (Us), Орто-Макнейл Фармасьютикал Инк. filed Critical Инсайт Сан Диего Инкорпорейтед (Us)
Publication of RU2004129752A publication Critical patent/RU2004129752A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2004129752/04A 2002-03-08 2003-03-07 Гетероциклические амидные промзводные для лечения диабета и других заболеваний RU2004129752A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36270202P 2002-03-08 2002-03-08
US60/362,702 2002-03-08

Publications (1)

Publication Number Publication Date
RU2004129752A true RU2004129752A (ru) 2005-05-10

Family

ID=27805215

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004129752/04A RU2004129752A (ru) 2002-03-08 2003-03-07 Гетероциклические амидные промзводные для лечения диабета и других заболеваний

Country Status (14)

Country Link
US (2) US7102000B2 (enExample)
EP (1) EP1487443A4 (enExample)
JP (1) JP2005530705A (enExample)
KR (1) KR20050006126A (enExample)
CN (1) CN1649586A (enExample)
AU (1) AU2003225682A1 (enExample)
CA (1) CA2478342A1 (enExample)
IL (1) IL163952A0 (enExample)
MX (1) MXPA04008733A (enExample)
NO (1) NO20044250L (enExample)
RU (1) RU2004129752A (enExample)
TW (1) TW200306184A (enExample)
WO (1) WO2003075924A1 (enExample)
ZA (1) ZA200408057B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60022207T2 (de) 1999-08-31 2006-06-22 Incyte San Diego Incorporated, San Diego Benzyliden-thiazolidindione und analoga und ihre verwendung zur behandlung von diabetes
BR0207846A (pt) * 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
WO2002072543A2 (en) * 2001-03-08 2002-09-19 Maxia Pharmaceuticals, Inc. Rxr activating molecules
EP1421061A4 (en) * 2001-08-17 2004-12-22 Incyte San Diego Inc OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US20050038098A1 (en) * 2003-04-18 2005-02-17 Catherine Tachdjian Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
EP1566202A1 (en) * 2004-02-23 2005-08-24 Sahltech I Göteborg AB Use of resistin antagonists in the treatment of rheumatoid arthritis
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
EP1788390B1 (en) * 2004-08-30 2010-04-14 Takeda Pharmaceutical Company Limited Screening method
JP2009512637A (ja) 2005-09-30 2009-03-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 異常脂血症、高コレステロール血症及び糖尿病の処置のためのrxrアゴニストとしてのジヒドロ−[1h]−キノリン−2−オン誘導体
WO2009143041A1 (en) 2008-05-20 2009-11-26 Merck & Co., Inc. Efficient production of heterologous proteins using mannosyl transferase inhibitors
WO2012153775A1 (ja) 2011-05-10 2012-11-15 国立大学法人神戸大学 Ras機能阻害作用を有するチオキソチアゾリジン誘導体
US10449254B2 (en) * 2013-11-03 2019-10-22 The Regents Of The University Of California Ionic liquids for transdermal drug delivery
WO2017213116A1 (ja) * 2016-06-07 2017-12-14 三菱電機株式会社 温度推定方法
KR102552848B1 (ko) 2016-08-29 2023-07-06 더 리전츠 오브 더 유니버시티 오브 캘리포니아 피부 치료를 위한 이온성 약제에 기초한 국소 제형
US10828265B2 (en) 2016-12-09 2020-11-10 The Regents Of The University Of California Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPS5538359A (en) 1978-09-12 1980-03-17 Hamari Yakuhin Kogyo Kk Preparation of 2-(3-benzoylphenyl)-propionic acid
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
DE3874257T2 (de) * 1987-03-11 1993-02-11 Kanegafuchi Chemical Ind Hydroxystyren-derivate.
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
JPS63230689A (ja) * 1987-03-18 1988-09-27 Tanabe Seiyaku Co Ltd ベンゾオキサジン誘導体
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
IE62214B1 (en) 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
CA2111445C (en) * 1991-07-22 1997-02-18 George J. Quallich Process for the preparation of intermediates in the synthesis of chiral thiazolidine-2,4-dione derivatives
DK0637297T3 (da) 1992-04-22 2000-09-18 Ligand Pharm Inc Forbindelser, der har selektivitet til retinoid-X-receptorer
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
ZA936492B (en) * 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
AU700706B2 (en) 1992-11-25 1999-01-14 Ligand Pharmaceuticals, Inc. RXR homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
US5691376A (en) * 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
HUT74611A (en) * 1994-02-17 1997-01-28 American Home Prod Biphenyl derivatives with phosphodiesterase inhibitor activity and pharmaceutical compns. contg. them
JPH09136877A (ja) 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
EP0850067A4 (en) 1995-07-17 1999-12-15 Cird Galderma METHODS OF TREATING CANCER USING 6- 3- 1-ADAMANTYL] -4-HYDROXYPHENYL]
JPH09176162A (ja) * 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
WO1997027191A1 (en) 1996-06-19 1997-07-31 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
WO1998001132A1 (en) * 1996-07-08 1998-01-15 Centre International De Recherches Dermatologiques Galderma Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
WO1999009965A2 (en) 1997-08-21 1999-03-04 Takeda Chemical Industries, Ltd. Anti-inflammatory agent
CA2309331A1 (en) 1997-11-12 1999-05-20 Institute Of Medicinal Molecular Design, Inc. Agent acting on retinoid receptor
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
ID27787A (id) 1998-08-21 2001-04-26 Viro Pharma Inc Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
WO2000018748A1 (en) 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
AU3111700A (en) 1998-12-04 2000-06-19 Structural Bioinformatics Inc. Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
DE60022207T2 (de) 1999-08-31 2006-06-22 Incyte San Diego Incorporated, San Diego Benzyliden-thiazolidindione und analoga und ihre verwendung zur behandlung von diabetes
US6380229B1 (en) 1999-11-12 2002-04-30 Fujimoto Co., Ltd. 2-(N-cyanoimino)thiazolidin-4-one derivatives
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
BR0207846A (pt) 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
WO2002072543A2 (en) 2001-03-08 2002-09-19 Maxia Pharmaceuticals, Inc. Rxr activating molecules
DE60204674T2 (de) 2001-03-14 2006-05-18 Eli Lilly And Co., Indianapolis Retinoid x rezeptormodulatoren
ATE442148T1 (de) 2001-04-04 2009-09-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
EP1421061A4 (en) * 2001-08-17 2004-12-22 Incyte San Diego Inc OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA
EP1456187A4 (en) * 2001-11-15 2005-02-09 Incyte San Diego Inc N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTERINEMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDER, CANCER AND OTHER DISEASES
AR037714A1 (es) * 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US20050014767A1 (en) * 2003-01-29 2005-01-20 Magnus Pfahl Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
US20050038098A1 (en) * 2003-04-18 2005-02-17 Catherine Tachdjian Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases

Also Published As

Publication number Publication date
MXPA04008733A (es) 2006-07-03
US20060241138A1 (en) 2006-10-26
TW200306184A (en) 2003-11-16
KR20050006126A (ko) 2005-01-15
EP1487443A1 (en) 2004-12-22
AU2003225682A2 (en) 2003-09-22
CA2478342A1 (en) 2003-09-18
EP1487443A4 (en) 2006-04-12
JP2005530705A (ja) 2005-10-13
US20030216432A1 (en) 2003-11-20
AU2003225682A1 (en) 2003-09-22
CN1649586A (zh) 2005-08-03
IL163952A0 (en) 2005-12-18
NO20044250L (no) 2004-11-03
US7102000B2 (en) 2006-09-05
WO2003075924A1 (en) 2003-09-18
ZA200408057B (en) 2007-05-30

Similar Documents

Publication Publication Date Title
RU2004129752A (ru) Гетероциклические амидные промзводные для лечения диабета и других заболеваний
US5391565A (en) Oxazolidine dione derivatives
DE60103976T2 (de) Pyrimidinylcarboxamiden als inhibitoren der pde4 isoenzyme
DE60203652T2 (de) Nikotinsäureamid-Derivate und ihre Mimetika als Inhibitoren von PDE4-Isozyme
JP2005530705A5 (enExample)
JP2817840B2 (ja) 置換チアゾリジンジオン誘導体の製造方法
WO2001074771A1 (en) Pyrrole-2,5-dione derivatives for the treatment of diabetes
JP2005525371A5 (enExample)
JP2972377B2 (ja) カテコール誘導体、その薬学的に許容しうる塩およびエステルならびにそれらを含有する医薬組成物
Mourão et al. Synthesis and biological activity of novel acridinylidene and benzylidene thiazolidinediones
EP3478677B1 (en) 1h-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof
US5599826A (en) Thiazolidinediones and drugs containing them
RU98117628A (ru) Замещенные производные тиазолидиндиона, способ их получения, фармкомпозиция
SK3202001A3 (en) Drug and a pharmaceutical composition for treating diabetes, insulin resistance, obesity, hyperglycemia, hyperinsulinemia or increased level
JP2005520858A (ja) 置換フェニル酢酸
CZ20031903A3 (cs) Amidové deriváty thiazolyl-, oxazolyl-, pyrrolyl- a imidazolyl karboxylových kyselin užitečné jako inhibitory isozymů PDE4
KR940019699A (ko) 옥사졸리딘디온 유도체, 그의 제조방법 및 용도
RU2009140769A (ru) Конденсированное бициклическое гетероарильное соединение
Storr et al. Vanadyl− Thiazolidinedione combination agents for diabetes therapy
HUE028595T2 (en) Nitrogen-containing aromatic heterocyclyl compound
RU2367659C2 (ru) Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar)
JP2023123607A (ja) ベンゼン誘導体
JP2002510623A (ja) 抗糖尿病薬
CN119562951A (zh) N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺
CN110709393A (zh) Ldha活性抑制剂

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20080213